What is Humanin?

Humanin is a mitochondria-derived peptide encoded within mitochondrial 16S rRNA. It is discussed for cytoprotection, neuroprotection, metabolism, and aging biology. [1][2][3]

The humanin family includes native humanin and more potent analogs such as HNG. Analog choice matters because potency and evidence can differ. [1][2][3]

Human biomarker and mechanistic interest is not an approved anti-aging or neuroprotective treatment. [1][2][3]

What Humanin is investigated for

Humanin evidence is grouped by practical use case and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

Oxidative-stress and anti-apoptotic protection

Injectable

42% Preliminary

Cytoprotection is the core Humanin mechanism, but it remains translational rather than clinical. [2][10][4]

Human evidence

Human clinical outcome evidence for Humanin cytoprotection is not established in the cited literature. [2][10][4]

Animal / mechanistic evidence

Reviews describe Humanin as a mitochondrial-derived peptide involved in apoptosis-related disease biology and cellular stress resistance. [2][10][4]

Neuroprotection and Alzheimer pathology

Injectable

40% Preliminary

Neuroprotection is a separate degenerative-disease rationale, not a proven cognitive treatment. [2][4][3]

Human evidence

Human Alzheimer or neurodegenerative outcome trials for Humanin are not established in the cited literature. [2][4][3]

Animal / mechanistic evidence

Degenerative-disease reviews connect Humanin with neuroprotection and apoptosis-related pathways relevant to Alzheimer pathology. [2][4][3]

Insulin sensitivity and metabolic aging

Injectable

32% Limited

Metabolic-aging support remains preclinical and should be separated from general cytoprotection. [11][9][8]

Human evidence

Human metabolic outcome trials for Humanin are not established in the cited literature. [11][9][8]

Animal / mechanistic evidence

Mitochondrial-derived peptide and diabetes-complication reviews support links to energy metabolism and insulin-sensitivity biology. [11][9][8]

Evidence snapshot

Overall confidence

Preliminary

42%

Humanin is a credible mitochondrial stress-response signal, not an approved therapy. Human outcome data are still too thin for strong metabolic or longevity conclusions. [1][2][3]

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

42%

Human evidence

Preliminary

Human biomarker and disease-association literature exists, but therapeutic outcome evidence remains limited. [1][2][3]

32%

Animal / preclinical

Limited

Animal and cell studies support cytoprotective, anti-apoptotic, and mitochondrial-stress plausibility. [1][2][3]

42%

Mechanism support

Preliminary

Humanin is studied as a cytoprotective signal that can influence apoptosis, oxidative stress, mitochondrial function, insulin sensitivity, and inflammation. The mechanism supports stress-response interest, not established treatment benefit. [1][2][3]

Forms & administration

Humanin is tracked as an injectable mitochondrial peptide. Humanin and analog discussions are separate from approved mitochondrial or metabolic medicines. [12][1][2]

Injectable

Dosing & protocols

The notes below separate published trial design from commonly discussed cosmetic or compounded-use patterns. They are educational context only, not a prescription or product instruction.

Typical Range

Common injectable protocols usually use 2-4 mg per day. [12][1][2]

Frequency

Common injectable schedules use once-daily dosing. [12][1][2]

Timing Considerations

Morning timing is the common anchor; workout or meal timing is less central than a consistent daily entry. [12][1][2]

Cycle Length

Common injectable blocks run 8-12 weeks before comparing energy, metabolic markers, and adverse-effect notes. [12][1][2]

What to expect

First 1-2 weeks

Injectable Humanin mitochondrial-support use may feel like shifts in energy, appetite regulation, sleep rhythm, or glucose-pattern stability. [1][2][3][12]

Weeks 4-8

Injectable metabolic and cognition-oriented blocks may show changes in fatigue, daily stamina, glucose patterns, and cognitive notes. [1][2][3][12]

After stopping

Energy or metabolic signals may soften as injectable Humanin exposure clears. [1][2][3][12]

Safety profile

Humanin safety is a mitochondrial and metabolic uncertainty question, with glucose, cell-survival biology, route, and product identity driving caution. [1][2][3]

Cautions

Glucose / metabolism [1][2][3]
Cancer-biology context [1][2][3]
Combination effects [1][2][3]
Product quality [1][2][3]

What we don't know

Human dose-response, long-term metabolic safety, cancer-biology implications, reproductive safety, and product consistency remain unclear. [1][2][3]

Who Humanin is not for

Route-specific avoid and medical-review notes:

Pregnancy or breastfeeding
Pregnancy or breastfeeding warrants medical review or avoidance for Humanin. [1][2][3]
Active cancer without specialist review
Active cancer without specialist review warrants medical review or avoidance for Humanin. [1][2][3]
Uncontrolled diabetes without clinician oversight
Uncontrolled diabetes without clinician oversight warrants medical review or avoidance for Humanin. [1][2][3]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Theoretical interactions

Glucose-lowering drugs
Insulin, sulfonylureas, GLP-1 drugs, or other glucose-lowering therapies can make metabolic response harder to interpret; this is a metabolic caution. [1][2][3]
Metabolic longevity stacks
Metformin, NAD+ products, MOTS-c, or AMPK-focused supplements can compound metabolic signals; this is a theoretical pathway caution. [1][2][3]
Oncology / growth-pathway products
Cancer therapies or growth-factor products can make cell-survival pathway effects difficult to interpret; this is a theoretical pathway caution. [1][2][3]

Regulatory status

United States

In the U.S. as of 2026-06-21, Humanin has no FDA-approved drug product for the reviewed injectable route. Research-market supply and compounded preparations are separate from approval; the 503A row names the current compounding bucket. [12][13][16][17]

Route	FDA drug approval	503A compounding
Injectable	Not Approved Humanin is not FDA-approved as an injectable drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval. [12][13][16][17]	Not Listed Humanin is not in the current reviewed 503A compounding bucket for the injectable route; compounding status is separate from FDA drug approval. [12][13][16][17]

Injectable

FDA drug approval

Not Approved

Humanin is not FDA-approved as an injectable drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval. [12][13][16][17]

503A compounding

Not Listed

Humanin is not in the current reviewed 503A compounding bucket for the injectable route; compounding status is separate from FDA drug approval. [12][13][16][17]

International

EU/Europe, UK, Canada, and Australia require product-specific checks in EMA/MHRA, Health Canada, and TGA registers. Research-market, supplement, or compounded availability should not be treated as therapeutic approval in those markets. [19][20][21][22]

Sports & competition

WADA S0 can apply to non-approved pharmacological substances that are not otherwise named. Tested athletes should not treat Humanin injectable route as athlete-cleared without sport-specific review. [14][12][13][16][17]

How it works

Humanin is a mitochondrial-derived peptide studied as a cytoprotective stress signal. Its mechanism literature connects apoptosis control, oxidative stress, mitochondrial function, insulin sensitivity, inflammation, and cardiovascular biology, which explains interest in aging and metabolic disease. [1][2][3]

Injectable humanin or analog exposure is a different claim from measuring endogenous humanin levels. Correlations in people and animal stress-response biology do not establish dose, tissue delivery, long-term safety, or reliable treatment outcomes for human protocols. Those gaps are especially important for chronic or wellness-oriented use. [1][2][3]

Research gaps & open questions

What the current literature has not yet settled about Humanin:

A key evidence gap is human pharmacokinetics for native peptide and analogs. [1][2][3]

A key evidence gap is controlled metabolic and neuroprotective trials. [1][2][3]

A key evidence gap is long-term safety and cancer-biology review. [1][2][3]

Common questions

Is humanin FDA-approved?

No. Humanin is not FDA-approved in the U.S. for injectable drug use, and research-market products are not FDA-approved. [12][13][1][2]

Is humanin mitochondrial?

Yes. Humanin belongs to the mitochondrial-derived peptide field and is studied as a cytoprotective stress signal, not an approved mitochondrial medicine. [12][13][1][2]

Does humanin reverse aging?

No. Human anti-aging treatment outcomes are not established; most Humanin claims remain mechanism, biomarker, animal, or early translational research. [12][13][1][2]

Myths & misconceptions

Myth

Humanin biomarker studies prove supplementation works.

Reality

A measured peptide level does not show that giving the peptide improves outcomes. [1][2][3]

Myth

All humanin analogs are interchangeable.

Reality

Native humanin and analogs can differ in potency and evidence. [1][2][3]

History & discovery

Humanin was first tied to neuroprotection and later became a core example in the mitochondrial-derived peptide field. Its history connects cellular stress biology with aging and metabolic interest. That distinction keeps the origin story tied to evidence strength, route, and product identity rather than broad clinical certainty. [1][2][3]

Early work linked humanin with protection against apoptosis-related cellular stress relevant to neurodegeneration models. That origin gave the peptide its survival-signal identity. [1][2][3]

Later reviews placed humanin among mitokines involved in mitochondrial stress, cardiovascular biology, insulin sensitivity, and aging markers. That expanded the field while keeping treatment evidence preliminary. [1][2][3]

Published research 14 studies

[1]

Role of humanin, a mitochondrial-derived peptide, in cardiovascular disorders.

Arch Cardiovasc Dis, 2020 Aug-Sep. review.

[2]

Humanin: A mitochondrial-derived peptide in the treatment of apoptosis-related diseases.

Life Sci, 2021 Jan 1. review.

[3]

Mitochondrial stress and mitokines in aging.

Aging Cell, 2023 Feb. review.

[4]

Mitochondrial-derived peptide humanin as therapeutic target in cancer and degenerative diseases.

Expert Opin Ther Targets, 2019 Feb. review.

[5]

The emerging role of mitochondrial derived peptide humanin in the testis.

Biochim Biophys Acta Gen Subj, 2021 Dec. review.

[6]

Mitochondrial-Derived Peptides Exacerbate Senescence.

Rejuvenation Res, 2018 Aug. review.

[7]

Mitochondrial-derived peptides and exercise.

Biochim Biophys Acta Gen Subj, 2021 Dec. review.

[8]

MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism.

Free Radic Biol Med, 2016 Nov. review.

[9]

Mitochondrial-derived peptides in energy metabolism.

Am J Physiol Endocrinol Metab, 2020 Oct 1. review.

[10]

The emerging role of the mitochondrial-derived peptide humanin in stress resistance.

J Mol Endocrinol, 2013 Feb. review.

[11]

Mitochondrial-Derived Peptides in Diabetes and Its Complications.

Front Endocrinol (Lausanne), 2021. review.

[12]

Drugs@FDA/openFDA query for Humanin

U.S. Food and Drug Administration. database query.

[13]

Compounding and the FDA: Questions and Answers

U.S. Food and Drug Administration. official guidance.

[14]

The 2026 List of Prohibited Substances and Methods

World Anti-Doping Agency. regulatory.